secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001558370-25-007060
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix BioTherapeutics Q1 revenue up 170% to $10.0M, net loss narrows to $3.6M
--------------------------------------------------------------------------------

- Revenues from selling goods $10.0M, up 170% YoY, driven by $5.9M increase in sales to Pfizer.
- Net loss $3.6M ($0.05/sh) vs $4.6M ($0.06/sh) in Q1 2024; cash $34.7M.
- Phase II trial of gout candidate PRX-115 expected to start H2 2025 after positive FIH results.
- R&D expenses $3.5M (+21% YoY) due to clinical pipeline advancement; SG&A down 16% to $2.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025007060/0001558370-25-007060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025007060/plx-20250509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer